<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246060</url>
  </required_header>
  <id_info>
    <org_study_id>CHIESI-NIS-003</org_study_id>
    <nct_id>NCT04246060</nct_id>
  </id_info>
  <brief_title>Observational Study to Assess the Quality of Life in Nephropathic Cystinosis Patients</brief_title>
  <acronym>PROREAL</acronym>
  <official_title>Multicentre, Ambispective, Observational, Real Life Study to Assess the Quality of Life Effectiveness of Extended Release (ER) Oral Cysteamine Therapy (Procysbi) in Belgian Patients Suffering From Nephropathic Cystinosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi SA/NV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi SA/NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Most of the real world evidence data related to efficacy of cysteamine therapy is
      retrospective. This study is a ambispective study to investigate the impact of cystine
      depletion therapy on the quality of life of patients and their parents.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to descriptively assess the change from baseline and percent change from baseline in the quality of life overall summary sores at 12 months in switch cohort</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Nephropathic Cystinosis</condition>
  <arm_group>
    <arm_group_label>Long term follow-up</arm_group_label>
    <description>Patients on extended release cysteamine treatment at study enrollment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Switch</arm_group_label>
    <description>Patients switching from immediate release cysteamine to extended release cysteamine during the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No switch</arm_group_label>
    <description>Patients remaining on immediate release cysteamine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procysbi</intervention_name>
    <description>75 mg and 25 mg</description>
    <arm_group_label>Long term follow-up</arm_group_label>
    <arm_group_label>Switch</arm_group_label>
    <other_name>cystagon</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        all Belgian nephropathic cystinosis patients.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  confirmed diagnosis of nephropathic cystinosis

          -  undergoing cystine depletion therapy with oral cysteamine

          -  signature of informed concent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zarha Vermeulen</last_name>
    <phone>0032472556669</phone>
    <email>z.vermeulen@chiesi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>sofie Geelissen</last_name>
    <email>s.geelissen@chiesi.com</email>
  </overall_contact_backup>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 27, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Cystinosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysteamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

